Zoledronic Acid Dosing and Administration Guidelines

Dosing by Indication

• For postmenopausal women with breast cancer, the American Society of Clinical Oncology recommends 4 mg IV every 6 months for 3-5 years 4
• The American Society of Clinical Oncology suggests that zoledronic acid should be initiated within 6 months of completion of chemotherapy or soon after surgery in postmenopausal women with breast cancer 4

Monitoring and Administration

• The National Comprehensive Cancer Network recommends serum creatinine measurement before each dose, as well as regular monitoring of serum calcium, electrolytes, phosphate, magnesium, and hematocrit/hemoglobin 5
• Intermittent evaluation for albuminuria every 3-6 months is recommended by the National Kidney Foundation 5

Efficacy Considerations

• Zoledronic acid has demonstrated efficacy across multiple tumor types, including breast cancer, prostate cancer, and multiple myeloma, with a significant reduction in skeletal-related events compared to placebo, according to the American Society of Clinical Oncology 2, 6